DISCLAIMERThe information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.
|You are receiving this because you have an account on www.oneGRAVESvoice.com|
|To unsubscribe from these emails, click here|
Trusted Resources: News & Meetings
Latest announcements and gatherings
Apitope, a clinical stage biotech company developing potential first-in-class antigen-specific immunotherapies targeting autoimmune diseases (including multiple sclerosis (MS), Graves’ disease and uveitis), today announced positive results from the Phase I first in man clinical trial of its product candidate, ATX-GD-59, in development for the treatment of Graves’ disease.
Graves’ disease is one of the most common autoimmune diseases with approximately 10 million patients across Europe and the US and yet there have been no innovative treatments in more than 60 years. With Graves’ disease, the immune system mistakenly attacks the thyroid gland and causes it to become overactive. Symptoms can include an enlargement of the thyroid gland, swelling of the neck, localised abnormalities of skin, tremors, heat intolerance and sweating, significant weight loss, osteoporosis, atrial fibrillation and ocular changes in patients. Each year 20-30 out of every 100,000 people are newly diagnosed with Graves’ disease.
Evidence & EducationThe Brazilian Consensus for the Diagnosis and Treatment of Hyperthyroidism: Recommendations by the Thyroid Departmen...Introduction: Hyperthyroidism is charac...
Community CenterWhat is Graves’ Disease? What is Hyperthyroidism? With Doctor David Schneider from University of WisconsinThis episode (interview with Dr. David S...
People & PlacesDavid Schneider, MD, MS, FACSDr. Schneider is certified by the Americ...
Evidence & EducationThyroidectomy as Primary Treatment Optimizes Body Mass Index in Patients With HyperthyroidismObjective: The purpose of this study wa...
News & MeetingsEarly, Effective Control of Graves’ Disease Improves Survival, Regardless of TreatmentAn early and intensive control of hypert...
People & PlacesBeth Israel Deaconess Medical Center – Thyroid CenterThe Thyroid Center, the Division of Endo...
Evidence & EducationRelation Between Therapy for Hyperthyroidism and the Course of Graves’ OphthalmopathyBackground: The chief clinical characte...
send a message
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.